This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Role of Lifestyle Factors in Breast Cancer-Related Outcomes

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by M.D. Anderson Cancer Center
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT02079662
First received: March 4, 2014
Last updated: March 27, 2017
Last verified: March 2017
  Purpose
The goal of this behavioral research study is to look at the relationship between lifestyle factors and cancer-related outcomes, such as the risk of the disease coming back, patient quality of life, physical functioning, and bodily reactions (such as hormones and immune function).

Condition Intervention
Breast Cancer Behavioral: Aerobic Activity Behavioral: Dietician Counseling Behavioral: Yoga Behavioral: Cognitive Behavior Therapy Behavioral: Smoking Cessation Counseling Behavioral: Questionnaires Other: Saliva Samples Behavioral: Dietary Assessment Procedure: Blood Samples

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Supportive Care
Official Title: The Role of Lifestyle Factors in Breast Cancer-Related Outcomes

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Disease-Free Survival (DFS) [ Time Frame: Baseline up to 5 years ]
    Disease-free survival (time to recurrence) where DFS is defined as the time from baseline (start of treatment) until the date on which disease recurrence/progression or death from any cause was documented (whichever occurred first).


Estimated Enrollment: 160
Actual Study Start Date: June 2013
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Integrative Oncology Group (IO)
Baseline measures collected prior to start of radiotherapy. Assessment includes battery of questionnaires. Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up. At baseline and follow ups, blood drawn to measure hormones and immune system responses. Accelerometer worn for 5 days. Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall. Participants have up to 7 different intervention sessions per week during course of radiotherapy for between 1 and 2 hours each session, up to 6 aerobic training sessions per week and one grocery store trip. Participants have a weekly meeting on the computer for 6 months, followed by a monthly meeting on computer from 6-12 months, and 2 hour meetings at all follow-up appointments during first year after radiotherapy. Follow-up assessments will take place during the last week of radiotherapy (+/- 2 weeks), and 2-4, 5-7, 11-13, 17-19, 23-25, 35-37, 47-49, and 59-61 months.
Behavioral: Aerobic Activity
30-60 minutes of moderate-to-vigorous intensity aerobic activity up to 6 days/week.
Behavioral: Dietician Counseling
Weekly meeting with dietician during radiotherapy to learn how to shop and cook during radiation therapy.
Behavioral: Yoga
Yoga based biweekly sessions with a mind-body instructor for about an hour.
Behavioral: Cognitive Behavior Therapy
Participants meet with a psychologist once a week during radiation treatment, during which time they take part in cognitive behavioral therapy to help support behavior changes.
Behavioral: Smoking Cessation Counseling
Smoking cessation treatment offered if participant smokes.
Behavioral: Questionnaires
Questionnaire completion at baseline, at end of radiation treatment, and at 3, 6, 12, 18, and 24 months after the end of radiation treatment, and then once a year for up to 3 years. This should take about 60-80 minutes.
Other Name: Surveys
Other: Saliva Samples
Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up.
Behavioral: Dietary Assessment
Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall.
Procedure: Blood Samples
At baseline and follow ups, blood drawn to measure hormones and immune system responses.
Active Comparator: Standard of Care (SC)
Baseline measures from participants collected prior to the start of radiotherapy. Assessment includes 60 to 90 minute-long battery of questionnaires. Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up. Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall. Follow-up assessments take place during the last week of radiotherapy (+/- 2 weeks), and 2-4, 5-7, 11-13, 17-19, 23-25, 35-37, 47-49, and 59-61 months. At baseline and follow ups, blood drawn to measure hormones and immune system responses.
Behavioral: Questionnaires
Questionnaire completion at baseline, at end of radiation treatment, and at 3, 6, 12, 18, and 24 months after the end of radiation treatment, and then once a year for up to 3 years. This should take about 60-80 minutes.
Other Name: Surveys
Other: Saliva Samples
Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up.
Behavioral: Dietary Assessment
Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall.
Procedure: Blood Samples
At baseline and follow ups, blood drawn to measure hormones and immune system responses.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women with Stage II or III breast cancer that will be scheduled to undergo a 4 to 6-week course of radiotherapy.
  2. Participants must be able to read, write, and speak English.
  3. Participants must be at least 18 years of age.
  4. Participants must be oriented to person, place, and time.
  5. Participants must also meet must also meet at least two of the following criteria related to lifestyle: 1) consume less than 3 servings of fruit and vegetable /day; 2) engage in less than 75 minutes moderate/vigorous activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling); and 3) engage in a mind-body practice less than 4 times a month.
  6. Participants must have a BMI of 24.45 or higher as assessed in the medical record.

Exclusion Criteria:

  1. Patients with a recurrent breast cancer diagnosis.
  2. Patients with another primary cancer diagnosis within 5 years of consent, not including non-melanoma skin cancers.
  3. Patients who have any major psychiatric diagnoses or thought disorder (e.g. Schizophrenia, Bi-polar disorder, Dementia).
  4. Patients with communication barriers (e.g., hard of hearing).
  5. Patients with extreme mobility issues (e.g. unable to get in and out of a chair unassisted).
  6. Patients with poorly or uncontrolled diabetes in the opinion of the physician(s).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02079662

Contacts
Contact: Lorenzo Cohen, PHD 713-745-4260

Locations
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: MD Anderson Cancer Center    877-632-6789      
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Lorenzo Cohen, PHD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT02079662     History of Changes
Other Study ID Numbers: 2012-0112
NCI-2014-02449 ( Registry Identifier: NCI CTRP )
Study First Received: March 4, 2014
Last Updated: March 27, 2017

Studies a U.S. FDA-regulated Drug Product: No

Keywords provided by M.D. Anderson Cancer Center:
Breast Cancer
Radiation Therapy
Radiotherapy
XRT
Aerobic Activity
Dietician Counseling
Dietary Assessment
Yoga
Cognitive Behavior Therapy
Smoking Cessation Counseling
Questionnaires
Surveys
Saliva Samples
Blood Samples

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 16, 2017